Site for EA1181 (CompassHER2-pCR): Preoperative THP and postoperative HP in patients who achieve a pathologic complete response

Brief description of study

The purpose of the study is to determine the safety and tolerability of pre-operative therapy with 12 weeks of taxane, trastuzumab (or FDA approved biosimilar) and pertuzumab. We are doing this study because we want to find out if this approach can enable you to take fewer chemotherapy drugs than the usual approach for your type of breast cancer without compromising your outcome. This would be a decrease in the total number of chemotherapy drugs and the amount of chemotherapy typically received to treat this type of cancer. We want to answer the research question: can participants with HER2-positive breast cancer who have no cancer remaining at surgery (either in the breast or underarm lymph nodes) after 12 weeks of chemotherapy and two HER-targeted therapies eliminate further chemotherapy after surgery?


Clinical Study Identifier: s20-01382
ClinicalTrials.gov Identifier: NCT04266249
Principal Investigator: Nina D'Abreo.
Other Investigators: Yelena Novik, Maryann J Kwa, Ruth Oratz, Marleen I Meyers, Amanda Marie Talmadge, Sylvia Adams, Caitlin Elizabeth Ryan, Danielle Seidman, Gregory Edward Totero, Anastasiya Apanasyuk, Alexander A Hindenburg, Natalie Jill Klar, Douglas K Marks.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.